

Brief Report

Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer



Kathleen A. Griffith, PhD, MPH, CRNP, Shijun Zhu, PhD, Meg Johantgen, PhD, RN, Michael D. Kessler, BS, Cynthia Renn, PhD, RN, Andreas S. Beutler, MD, Rahul Kanwar, MS, Nicholas Ambulos, PhD, Guido Cavaletti, MD, Jordi Bruna, MD, PhD, Chiara Briani, MD, Andreas A. Argyriou, MD, DSc, Haralabos P. Kalofonos, MD, Laura M. Yerges-Armstrong, PhD, and Susan G. Dorsey, PhD, RN, FAAN
 Department of Pain and Translational Symptom Science (K.A.G., C.R., S.G.D.), School of Nursing, University of Maryland, Baltimore, Maryland; Program in Oncology (K.A.G., C.R., N.A., S.G.D.), University of Maryland School of Medicine, Baltimore, Maryland; Department of Organizational Systems and Adult Health (S.Z., M.J.), School of Nursing, University of Maryland, Baltimore, Maryland; Program in Personalized and Genomic Medicine (M.D.K., L.M.Y.-A.), University of Maryland School of Medicine, Baltimore, Maryland; UM Center to Advance Chronic Pain Research (C.R., S.G.D.), University of Maryland, Baltimore, Maryland; Department of Oncology and the Cancer Center (A.S.B., R.K.), Mayo Clinic, Rochester, Minnesota; Department of Microbiology and Immunology (N.A.), School of Medicine, University of Maryland, Baltimore, Maryland, USA; School of Medicine and Surgery (G.C.), Experimental Neurology Unit and Milan Center for Neuroscience, University of Milano-Bicocca, Monza (MB), Italy; Unit of Neuro-Oncology (J.B.), Bellvitge University Hospital-ICO Duran and Reynals, L'hospitale Barcelona, Spain; Department of Neurosciences (C.B.), University of Padua, Padua, Italy; and Division of Oncology (A.A.A., H.P.K.), Department of Medicine, University Hospital of Patras, Rion-Patras, Greece

Abstract

Context. Oxaliplatin-induced peripheral neuropathy (OIPN) is a dose-limiting toxicity of oxaliplatin and affects most colorectal cancer patients. OIPN is commonly evaluated by patient symptom report, using scales to reflect impairment. They do not discriminate between unique grouping of symptoms and signs, which impedes prompt identification of OIPN.

Objective. The objective of this study was to identify clusters of symptoms and signs that differentiated underlying clinical severity and segregated patients within our population into OIPN subgroups.

Methods. Chemotherapy-naïve colorectal cancer patients ($N = 148$) receiving oxaliplatin were administered the Total Neuropathy Score clinical (TNSc[®]), which includes symptom report (sensory, motor, autonomic) and sensory examination (pin sense, vibration, reflexes). The TNSc was administered before chemotherapy initiation (T0) and after cumulative doses of oxaliplatin 510–520 mg/m² (T1) and 1020–1040 mg/m² of oxaliplatin (T2). Using mean T2 TNSc scores, latent class analysis grouped patients into OIPN severity cohorts.

Results. Latent class analysis categorized patients into four distinct OIPN groups: low symptoms and low signs ($n = 54$); low symptoms and intermediate signs ($n = 44$); low symptoms and high signs ($n = 21$); and high symptoms and high signs ($n = 29$). No differences were noted among OIPN groups on age, sex, chemotherapy regimen, or cumulative oxaliplatin dose.

Conclusion. We identified OIPN patient groups with distinct symptoms/signs, demonstrating variability of OIPN presentation regardless of cumulative oxaliplatin dose. Over half of the sample had positive findings on OIPN examination despite little or no symptoms. Sensory examination of all patients receiving oxaliplatin is indicated for timely identification of OIPN, which will allow earlier symptom management. *J Pain Symptom Manage* 2017;54:701–706. © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Key Words

Chemotherapy-induced peripheral neuropathy, oxaliplatin, pain, chronic pain, latent class analysis, measurement

Address correspondence to: Kathleen A. Griffith, PhD, MPH, CRNP, The George Washington University School of Nursing, 1919 Pennsylvania Avenue, Room 544, Washington, DC 20006, USA. E-mail: kgriffith@gwu.edu

Accepted for publication: July 18, 2017.

Introduction

Oxaliplatin, a third-generation platinum-based agent, is the principal chemotherapeutic agent for the treatment of colorectal cancer (CRC) and is also used in patients with pancreatic, gastric, and other cancers.^{1–3} Although oxaliplatin has improved overall survival rate,^{4–6} oxaliplatin-induced peripheral neuropathy (OIPN) remains a treatment-limiting factor.^{7,8} Some degree of OIPN occurs in nearly all patients,⁶ and approximately two-thirds will have symptoms one-year post-treatment or beyond.^{9,10} OIPN has been reported as dose dependent, with symptoms more likely to occur as the cumulative dose exceeds 780–850 mg/m². Unlike acute OIPN that is transient, chronic OIPN can persist for months or years^{11,12} and includes pain, numbness, and dysesthesias that lead to reduced quality of life and function.¹³ Little is known about how individual symptoms are related and whether they co-occur, which limits the management options and early identification of OIPN. Groupings of OIPN patients that better represent distinctions in underlying disease phenomena may facilitate better identification of those who require earlier or more targeted treatment.

Although predictors of OIPN have been identified, including chemotherapy treatment schedule, cumulative drug dose, and pre-existing peripheral neuropathy,^{14,15} currently there is no effective strategy for preventing OIPN and pharmacologic management is limited.^{16,17} In some cases, OIPN severity may require prolongation of oxaliplatin administration time, dose reduction, treatment delay, or drug discontinuation to avoid irreversible sensory nerve damage,^{18–20} although evaluation of such management approaches in clinical trials has not resulted in reduced OIPN severity.²¹

The Total Neuropathy Score clinical (TNSc) version is a seven-item composite measure of impairment and has been well validated in chemotherapy-induced peripheral neuropathy (CIPN).²² Composite scales incorporate results from self-report items and clinician examination to provide a complete profile of symptoms and signs and, thus, characterize the phenomenon. Latent class analysis (LCA) is an approach for identifying unmeasured group or cohort membership within a patient population and can be used with categorical data. The purpose of our analysis was to identify clusters of symptoms and signs that differentiated underlying clinical severity and segregated patients within our population into distinct subgroups of OIPN.

Methods

The details of the original study have been previously reported.²³ In brief, 200 CRC patients scheduled to receive oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX) or oxaliplatin plus capecitabine (XELOX), either in the adjuvant or metastatic setting, were

enrolled in a multisite study. The study was conducted at four centers in three European countries after Institutional Review Board approval at all four centers.

Eligibility criteria included: 1) preparation to receive oxaliplatin-based chemotherapy for CRC, 2) no evidence of other systemic disease or peripheral neuropathy, 3) life expectancy of more than nine months; 4) Karnofsky performance score ≥ 70 , and 5) ability to understand study information delivered by investigators. Additional exclusion criteria included history or evidence of pre-existing peripheral neuropathy at baseline screening, co-morbidities, such as diabetes, alcohol abuse (>5 IU/d), and any other condition or medication that could interfere or complicate the clinical assessments.

Participants were followed prospectively and monitored for OIPN development and severity at three time points during chemotherapy with the TNSc composite instrument. The TNSc was administered before chemotherapy initiation (T0), following 510–520 mg/m² of oxaliplatin (T1), and following 1020–1040 mg/m² of oxaliplatin (T2). The TNSc is a seven-item scale (sensory, motor and autonomic symptoms, pinprick, vibration, light touch, deep tendon reflex [DTR], strength), each scored 0–4, with higher scores indicating greater impairment.^{24–26}

This study used de-identified participant data from the original study and was designated by the University of Maryland IRB as nonhuman subjects' research. The number of participants with data sufficient for LCA approach was $N = 148$.

Analysis

Data from the primary study were abstracted into a data file for analysis. LCA was used to stratify OIPN phenotypes derived from the TNSc scoring instrument. The strength item was removed from the LCA procedure because all participants scored 0. The final number of TNSc items for LCA was 6, therefore, with a potential score range of 0–24. LCA (Mplus 7.0)²⁷ produced mutually exclusive participant classes based on OIPN patient-reported symptoms and clinical examination signs. To determine the number of classes in the mixture modeling, we chose the Lo, Mendell, and Rubin likelihood ratio test,²⁸ which statistically compares the fit of a given model with the fit of a model with one fewer class. Once the class membership was determined, chi-square tests for categorical variables and ANOVA for continuous variables were used to compare the differences with regard the patients' demographic and clinic characteristics across the classes.

Results

Participants had an average age of 63 years, were primarily men, and had nonmetastatic disease (67%).

Table 1
Participant Characteristics and TNSc Values Overall and Within Each OIPN Severity Group (N = 148)

Characteristics	Total, n (%)	Class 1: Low/Low, n = 54, n (%)	Class 2: Low/Inter, n = 44, n (%)	Class 3: Low/High, n = 21, n (%)	Class 4: High/High n = 29, n (%)	PValue
Age, mean (SD)	63.3 (9.1)	63.7 (8.4)	64.0 (9.4)	64.5 (7.3)	60.7 (10.8)	0.363
Gender						0.058
Male	92 (62.2)	32 (59.3)	26 (59.1)	10 (47.6)	24 (82.8)	
BSA, m ² , mean (SD)	1.74 (.22)	1.68 (.26)	1.73 (.21)	1.76 (.14)	1.83 (.20)	0.032
Cumulative oxaliplatin at T2, dose/m2 mean (SD)	963.4 (145.4)	962.9 (142.4)	951.1 (163.6)	962.0 (154.3)	984.0 (117.8)	0.829
TNSc (T1), mean (SD)	2.4 (3.5)	0.06 (.3)^a	1.0 (1.5)^b	3.9 (2.1)^{ab}	7.9 (3.5)^{ab}	<0.001
TNSc (T2), mean (SD)	5.9 (5.5)	0.2 (.6)	5.5 (1.2)	9.7 (.9)	14.6 (.6)	<0.001

OIPN = oxaliplatin-induced peripheral neuropathy; TNSc = Total Neuropathy Score clinical.

P-values calculated from either chi-square or ANOVA tests. Values in bold indicates groups that were significantly different in the post hoc pairwise comparisons. Differences between groups at TNSc T1 are identified further with matching superscript alphabets.

Participant characteristics can be found in Table 1. The LCA results, based on T2 final TNSc scores in this longitudinal study, demonstrated a statistically significant, best-fitting model of four latent classes (Supplemental Table 1). The LCA stratified the CRC participants into four phenotype groups: Class 1: low symptoms and low signs ($n = 54$), indicating that both patient report and provider examination revealed little or no OIPN; Class 2: low symptoms and intermediate signs ($n = 44$), meaning that patients complained of little to no symptoms but examination findings showed some OIPN; Class 3: low symptoms and high signs ($n = 21$), with patients complaining of little to no symptoms but examination findings showed clear OIPN; and Class 4: high symptoms and signs ($n = 29$), which indicated high levels of patient-reported symptoms with correspondingly high examination findings (Fig. 1).

There was no significant difference in age, gender, or OIPN regimen among the four severity groups (Table 1). As expected, the low OIPN group had statistically significant lower overall TNSc scores than the high OIPN group at time of chemotherapy

completion ($P < 0.001$). Body surface area was higher in the Class 4 group, where symptom report and clinical examination findings were most severe.

Discussion

Our rigorously phenotyped sample of OIPN in a chemotherapy-naïve, homogeneous population of CRC participants from a prospective trial allowed analysis of data without the influence of other diseases or pre-existing neuropathy. Previous investigators have used traditional methods of phenotyping based on the total scores of ordinal-based measures and simple classification of OIPN with scales such as the National Cancer Center Common Toxicity Criteria of Adverse Events. Our LCA approach used a least-squares model to categorize OIPN features by assessing how individual items within the TNSc form discrete groups or classes. Using a composite measure of patient symptom report and clinical examination, the LCA method provided a robust definition of OIPN severity and distinguished distinct clinical groups. Routine evaluation of both patient symptoms and clinical signs of OIPN may be more accurate for defining OIPN.

The TNSc has been validated in a number of studies and has demonstrated very good reproducibility indices. The American Society of Clinical Oncology recommends using TNSc for ongoing assessment of CIPN in survivor populations, given the combination of subjective and objective measurements thought to strengthen its surveillance value.¹⁶ Additional credence of the TNSc has been demonstrated with a Rasch transformation of ordinal-based TNSc to an interval-based one, indicating that the TNSc properties are suitable for parametric testing and supporting its continued use in the longitudinal setting.²⁹ In sum, performing an LCA clustering of OIPN phenotypes using the TNSc clinical assessment scores is robust and facilitates the effective clinical classification of OIPN patients.

The recognition of four phenotypic groups may be clinically meaningful, in that it will help identify




Fig. 1. Mean TNSc scores for each item within OIPN severity group. OIPN = oxaliplatin-induced peripheral neuropathy; TNSc = Total Neuropathy Score clinical.

distinct OIPN states. The literature confirms that some patients do not experience any OIPN symptoms over the course of chemotherapy,³⁰ and we identified a similar low symptoms/signs group, which comprised 36% of the sample. Group 2, representing 30% of the sample, had mild sensory symptoms accompanied by positive findings on physical examination (reduced pin sense, vibration sense, and reflexes). It is possible that Group 2 may be at highest risk of having OIPN overlooked if only a report of symptoms is relied on. Based on our findings, a sensory examination is recommended in all patients receiving oxaliplatin, even if no symptoms are present. In our view, to detect even subclinical changes is essential to eventually be able to accurately follow up the course of OIPN. Groups 3 and 4 were analytically distinct; these groups include patients most likely to be diagnosed with OIPN in the clinic because they exhibited both OIPN symptoms and signs. Still, these groups may represent patients with different functional profiles and exploration of their experiences during treatment may help clarify their treatment needs.

As described in Figure 1, DTRs followed by pin sense were the most impaired examinations in our analysis. DTRs are a measure of the sensorimotor system, and reduced response is an indication of sensory neuropathy in the setting of OIPN. Reduced DTRs have been shown to occur in association with hypoesthesia using current perception threshold in the setting of CIPN.³¹ We have also reported reduced vibration perception in combination with reduced DTRs using TNSc, where DTRs were the most sensitive component of the neurologic examination in CIPN.³² With toxic neuropathies, there is a predominant spectrum, such as sensory impairment in the case oxaliplatin, but not all the sensory neurons demonstrate the same susceptibility to damage. For example, the unmyelinated c fibers are generally preserved in OIPN with differential impairment of A α fibers, which are responsible for innervating the muscle spindle. For this reason, we observed a worse impairment in DTRs compared with other sensory tests.

Autonomic symptom scores were low except in those with the most severe signs and symptoms. A longitudinal study of oxaliplatin using self-report measurement of autonomic symptoms demonstrates minor change overall in autonomic vs. sensory symptoms over the course of treatment.³³ Our findings echo these data except that we found pronounced autonomic symptoms in the high symptoms and signs group. This exception underscores the strength of the LCA use to unmask unique groupings of OIPN presentation.

We found that as body surface area increased so did OIPN severity, with differences noted between classes 1 and 4, although cumulative doses of oxaliplatin were not different between groups. This has been

documented elsewhere³⁴ and warrants further examination. However, based on our findings, body surface area alone places patients at increased risk for OIPN because those with obesity-related comorbidities, such as diabetes, were excluded from the study. Although the relationship among obesity, CIPN, and pain has been documented across chemotherapy regimens and primary disease sites,³⁵ a pathogenic mechanism has not been proposed. Nonetheless, the increased risk of OIPN in overweight and obese patients warrants careful monitoring during chemotherapy.

The OIPN groups identified in this analysis may explain why some pharmacologic treatments, such as serotonin norepinephrine reuptake inhibitors (SNRIs), are more effective in some patients than in others. Our analysis will provide important information to those studying SNRI management in chemotherapy-induced neuropathic pain. It is possible that earlier initiation of SNRIs at the point of examination abnormality and before positive sensory symptoms onset may attenuate painful symptom development, although such determinations will be made by those conducting research into the mechanisms of SNRI action in the setting of OIPN. Identifying who may benefit from duloxetine or venlafaxine is especially important given the dearth of effective interventions for OIPN. Furthermore, it is possible that earlier symptom intervention produces better responses. For some patients, there is a role for medications, such as anti-convulsants and SNRIs, and more prompt initiation may produce better responses by reducing the positive sensory symptom burden. In particular, anticonvulsants acting through the voltage-gated sodium channel blockade, such as carbamazepine, oxcarbazepine, or even lacosamide, deserve to be further tested. They may have potential as a symptomatic and maybe preventive intervention in OIPN, based on their ability to target central and peripheral sensitization mechanisms.^{36,37} Improving the accuracy of OIPN identification, especially in individuals with limited symptom profiles, may allow closer surveillance and more immediate intervention when indicated. An ideal pharmacologic approach for OIPN management is currently lacking as both SNRIs and anticonvulsants only alleviate the component of neuropathic pain in OIPN and are generally not useful to reduced negative sensory symptoms, such as numbness. As such, nonpharmacologic treatment strategies for OIPN management should be also considered, including the "Stop-and-Go" concept, which uses the predictability and reversibility of neurologic symptoms, to aim at delivering higher cumulative OXL doses as long as the therapy is still effective.²¹ Other promising interventions might include exercise³⁸ and possibly neuromodulation via spinal cord electrical stimulation or neurocutaneous stimulation.³⁹

Although our study has many strengths, including large sample size of homogeneous patients and excellent measurement of OIPN, the use of secondary data precludes measurement of variables that are not available in the existing data set. For example, depression, which has more recently been shown to commonly co-occur in chemotherapy-induced neuropathy⁴⁰ may have provided further post hoc elucidation of how groups are formed. We used only final TNSc scores to conduct our LCA, and in future describing patients at mid-treatment and observing how OIPN severity group membership may change over time could be helpful for additional insights about the OIPN phenotype.

From a clinical standpoint, the identification of four groups of OIPN symptom and sign combinations demonstrates that there is significant variability in OIPN manifestation, severity, and presentation. All patients should be examined for signs of OIPN, even if they do not complain of symptoms. Our results will help clinicians to treat patients earlier and more accurately.

Disclosures and Acknowledgments

This work was supported by the National Institutes of Health (P30NR014129 to SGD), National Institutes of Health (K01HL116770 to LMYA), and FondazioneCarplo (2013-0842 to G. C.). K. A.G. holds a TNSc copyright. When licensed, she is paid royalties. There was no license for its use in this study. TNSc is copyrighted by Johns Hopkins University. The authors declare no conflicts of interest.

References

1. Kim DY, Kim JH, Lee SH, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. *Ann Oncol* 2003;14:383–387.
2. Nicoletto MO, Falci C, Pianalto D, et al. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. *Gynecol Oncol* 2006;100:318–323.
3. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. *Clin Cancer Res* 2005;11(2 Pt 1):690–696.
4. Comella P, Lorusso V, Maiorino L, et al. Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. *Cancer Chemother Pharmacol* 2009;64:893–899.
5. de Gramont A, Banzi M, Navarro M, et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial. *Proc Am Soc Clin Oncol* 2003;22:151.
6. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med* 2004;350:2343–2351.
7. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. *Semin Oncol* 2002;29(5 Suppl 15):21–33.
8. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2000;18:136–147.
9. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. *Pain* 2014;155:2461–2470.
10. Beijers AJ, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. *Support Care Cancer* 2014;227:1999–2007.
11. Briani C, Argyriou AA, Izquierdo C, et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. *J Peripher Nerv Syst* 2014;19:299–306.
12. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. *J Clin Oncol* 2013;31:2699–2707.
13. Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors. *Support Care Cancer* 2013;21:3307–3313.
14. Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S. Predicting acute and persistent neuropathy associated with oxaliplatin. *Am J Clin Oncol* 2013;36:331–337.
15. Velasco R, Bruna J, Briani C, et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. *J Neurol Neurosurg Psychiatry* 2014;85:392–398.
16. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2014;32:1941–1967.
17. Balayssac D, Ferrier J, Descœur J, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. *Expert Opin Drug Saf* 2011;10:407–417.
18. Boyette-Davis J, Dougherty PM. Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. *Exp Neurol* 2011;229:353–357.
19. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity. *Cancer* 2013;119:438–444.
20. Altaf R, Lund Brixen A, Kristensen B, Nielsen SE. Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. *Oncology* 2014;87:167–172.
21. Tournigand C, Cervantes A, Figuer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with

- oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. *J Clin Oncol* 2006;24:394–400.
22. Cavaletti G, Cornblath DR, Merkies IS, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. *Ann Oncol* 2012;24:454–462.
23. Argyriou AA, Cavaletti G, Antonacopoulou A, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. *Cancer* 2013;119:3570–3577.
24. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. *Neurology* 1999;53:1660–1664.
25. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. *J Peripher Nerv Syst* 2007;12:210–215.
26. Smith EM, Cohen JA, Pett MA, Beck SL. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinum. *Cancer Nurs* 2010;33:173–183.
27. Muthén LK, Muthén BO. *Mplus user's guide*. 7th ed. Los Angeles: Muthen & Muthen
28. Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo Simulation study. *Struct Equ Model A Multidiscip J* 2007;14:535–569.
29. Binda D, Cavaletti G, Cornblath DR, Merkies IS. Rasch-transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy. *J Peripher Nerv Syst* 2015;20:328–332.
30. Ventzel L, Jensen AB, Jensen AR, Jansen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. *Eur J Cancer* 2015;51:S206.
31. Griffith KA, Couture DJ, Zhu S, et al. Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. *Support Care Cancer* 2014;22:1161–1169.
32. Argyriou AA, Polychronopoulos P, Koutras A, et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted? *Support Care Cancer* 2005;13:647–651.
33. Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). *J Clin Oncol* 2015;33:3416–3422.
34. Ottaiano A, Nappi A, Tafuto S, et al. Diabetes and body mass index are associated with neuropathy and prognosis in colon cancer patients treated with capecitabine and oxaliplatin adjuvant chemotherapy. *Oncology* 2016;90:36–42.
35. Cox-Martin E, Trahan LH, Cox MG, Dougherty PM, Lai EA, Novy DM. Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy. *Support Care Cancer* 2017;25:1873–1879.
36. Argyriou AA, Chroni E, Polychronopoulos P, et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. *Neurology* 2006;67:2253–2255.
37. Argyriou AA, Bruna J, Marmioli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. *Crit Rev Oncol Hematol* 2012;82:51–77.
38. Streckmann F, Kneis S, Leifert JA, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. *Ann Oncol* 2014;25:493–499.
39. Majithia N, Loprinzi CL, Smith TJ. New practical approaches to chemotherapy-induced neuropathic pain: prevention, assessment, and treatment. *Oncology (Williston Park)* 2016;30:1020–1029.
40. Hwang KH, Cho OH, Yoo YS. Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life. *Eur J Oncol Nurs* 2015;21:215–222.

Supplemental Table 1
Latent Class Analysis Results

	H0	H1	Number of Free Parameters	AIC	BIC	Sample Size		LMR LRT Test ^a		Bootstrap	Number of Patients in Each Class
Number of Classes	LL	LL				Adj. BIC	Entropy	Test Value	PValue	LRT PValue ^a	
2	−1231.88	−873.677	19	1785.354	1842.301	1782.173	0.997	716.411	<0.001	<0.001	95/52
3	−873.677	−641.128	26	1334.255	1412.183	1329.903	0.990	465.098	0.049	<0.001	54/44/50
4	−641.128	−502.197	33	1070.940	1169.302	1064.869	0.999	277.862	0.032	<0.001	54/44/21/29
5	−502.197	−408.515	40	897.031	1016.919	890.334	1.000	187.363	0.642	<0.001	54/41/26/11/16

adj. = adjusted; LL = log-likelihood; LMR = Lo-Mendell-Rubin; LRT = likelihood ratio test; AIC = Akaike information criterion; BIC = Bayesian information criterion.

^a $n - 1$ classes (H0) vs. n classes.